Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1342

1.
2.

Methylphenidate Induced Acute Dystonic Reaction.

Uzun ME, Korkmaz MF, Ekici A, Kaymaz N.

Indian J Pediatr. 2018 Jul;85(7):577. doi: 10.1007/s12098-018-2711-3. Epub 2018 May 23. No abstract available.

PMID:
29790008
3.

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, Moreira-Maia CR, Magnusson FL, Holmskov M, Gerner T, Skoog M, Rosendal S, Groth C, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Håkonsen SJ, Aagaard L, Simonsen E, Gluud C.

Cochrane Database Syst Rev. 2018 May 9;5:CD012069. doi: 10.1002/14651858.CD012069.pub2. Review.

PMID:
29744873
4.

Pharmacological interventions for apathy in Alzheimer's disease.

Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL.

Cochrane Database Syst Rev. 2018 May 4;5:CD012197. doi: 10.1002/14651858.CD012197.pub2. Review.

PMID:
29727467
5.

QTc prolongation after ADHD medication.

Snircova E, Marcincakova Husarova V, Ondrejka I, Hrtanek I, Farsky I, Nosalova G.

Neuro Endocrinol Lett. 2018 Feb;38(8):549-554.

PMID:
29504733
6.

Methylphenidate regulation of osteoclasts in a dose- and sex-dependent manner adversely affects skeletal mechanical integrity.

Uddin SMZ, Robison LS, Fricke D, Chernoff E, Hadjiargyrou M, Thanos PK, Komatsu DE.

Sci Rep. 2018 Jan 24;8(1):1515. doi: 10.1038/s41598-018-19894-x.

7.

Resolution of methylphenidate osmotic release oral system-induced hair loss in two siblings after dose escalation.

Ardic UA, Ercan ES.

Pediatr Int. 2017 Nov;59(11):1217-1218. doi: 10.1111/ped.13414.

PMID:
29359460
8.

Newly Developed Skin Picking After Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder: Possible Mechanisms.

Kara T, Akaltun İ.

Clin Neuropharmacol. 2018 Jan/Feb;41(1):28-30. doi: 10.1097/WNF.0000000000000262.

PMID:
29298167
9.

Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?

Svendsen K, Halvorsen KH, Vorren S, Samdal H, Garcia B.

Eur J Clin Pharmacol. 2018 Apr;74(4):497-504. doi: 10.1007/s00228-017-2396-y. Epub 2017 Dec 18.

PMID:
29255992
10.

[Does methylphenidate cause liver damage? An analysis of ad hoc reports to the "Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)"].

Fekete S, Romanos M, Gerlach M.

Z Kinder Jugendpsychiatr Psychother. 2018 Jul;46(4):342-348. doi: 10.1024/1422-4917/a000565. Epub 2017 Dec 14. German.

PMID:
29237323
11.

A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study).

Hegerl U, Mergl R, Sander C, Dietzel J, Bitter I, Demyttenaere K, Gusmão R, González-Pinto A, Zorrilla I, Alocén AG, Sola VP, Vieta E, Juckel G, Zimmermann US, Bauer M, Sienaert P, Quintão S, Edel MA, Bolyos C, Ayuso-Mateos JL, López-García P, Kluge M.

Eur Neuropsychopharmacol. 2018 Jan;28(1):185-194. doi: 10.1016/j.euroneuro.2017.11.003. Epub 2017 Nov 23.

PMID:
29174864
12.

Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.

Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, López FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH.

J Child Adolesc Psychopharmacol. 2017 Aug;27(6):474-482. doi: 10.1089/cap.2017.0084. Epub 2017 Jul 21.

13.

Cotempla XR-ODT--another long-acting methylphenidate for ADHD.

[No authors listed]

Med Lett Drugs Ther. 2017 Nov 6;59(1533):183-185. No abstract available.

PMID:
29125594
14.

Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study.

Liang SH, Yang YH, Kuo TY, Liao YT, Lin TC, Lee Y, McIntyre RS, Kelsen BA, Wang TN, Chen VC.

Res Dev Disabil. 2018 Jan;72:96-105. doi: 10.1016/j.ridd.2017.10.023. Epub 2017 Nov 6.

15.

Placental Complications Associated With Psychostimulant Use in Pregnancy.

Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Patorno E, Mogun H, Huybrechts KF.

Obstet Gynecol. 2017 Dec;130(6):1192-1201. doi: 10.1097/AOG.0000000000002362.

16.

Methylphenidate, cognition, and epilepsy: A 1-month open-label trial.

Adams J, Alipio-Jocson V, Inoyama K, Bartlett V, Sandhu S, Oso J, Barry JJ, Loring DW, Meador KJ.

Epilepsia. 2017 Dec;58(12):2124-2132. doi: 10.1111/epi.13917. Epub 2017 Oct 9.

17.

Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.

Park-Wyllie L, van Stralen J, Castillon G, Sherman SE, Almagor D.

Clin Ther. 2017 Oct;39(10):2006-2023. doi: 10.1016/j.clinthera.2017.08.018. Epub 2017 Oct 6.

18.

Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies.

Danborg PB, Simonsen AL, Gøtzsche PC.

Int J Risk Saf Med. 2017;29(1-2):107-124. doi: 10.3233/JRS-170743. Review.

19.

Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate.

Díez-Suárez A, Vallejo-Valdivielso M, Marín-Méndez JJ, de Castro-Manglano P, Soutullo CA.

J Child Adolesc Psychopharmacol. 2017 Oct;27(8):723-730. doi: 10.1089/cap.2016.0150. Epub 2017 Aug 17.

PMID:
28817309
20.

A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.

Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A.

J Clin Psychopharmacol. 2017 Oct;37(5):590-594. doi: 10.1097/JCP.0000000000000747.

PMID:
28806385

Supplemental Content

Loading ...
Support Center